• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
AIDS Patient Care STDS. Author manuscript; available in PMC Jun 10, 2008.
Published in final edited form as:
PMCID: PMC2423809

Hepatitis C Infection Is Associated with Lower Lipids and High-Sensitivity C-Reactive Protein in HIV-Infected Men



Increased cardiovascular risk has been linked to HIV infection and combination antiretroviral therapy, but the impact of hepatitis C virus (HCV) status on indices of cardiovascular risk has not been routinely assessed in the HIV-infected population. The objective of this study was to analyze associations of HCV, HIV, and combination antiretroviral therapy with lipid levels and C-reactive protein (CRP) among older men. We measured fasting total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride, and high-sensitivity CRP serum levels in a cross-sectional study of 108 HIV-infected and 74 HIV-uninfected at-risk older men. One hundred ten men (60%) had detectable HCV RNA, with no difference by HIV status (p = 0.25). The majority (88%) of men with HCV infection had a history of injection drug use. Among all men, HCV infection was independently associated with lower total cholesterol (p < 0.001), LDL-C (p < 0.001), triglycerides (p = 0.01), and CRP (p < 0.001). Among HIV-infected men, HCV infection was associated with lower total cholesterol (p < 0.001), LDL-C (p < 0.001), and CRP (p = 0.004). HCV infection was associated with lower triglycerides among men on protease inhibitors (PI) (p = 0.02) and non-PI combination antiretroviral therapy (p = 0.02), but not among antiretroviral-naïve men. These findings demonstrate an association of lower serum lipid and CRP levels with HCV infection and suggest that HCV status should be assessed as an important correlate of cardiovascular risk factors in studies of older men with or at risk for HIV.


Highly active antiretroviral therapy (HAART), which has greatly improved survival among HIV-infected persons, has been linked to dyslipidemia and increased cardiovascular risk.15 HIV infection is also associated with C-reactive protein (CRP), a more recently identified cardiovascular risk factor.6 However, studies of cardiovascular disease among HIV-infected persons have not consistently shown increased rates of atherosclerosis in association with HIV infection or HAART use.35,79 Investigation of other factors that may influence cardiovascular risk in the HIV-infected population is therefore important.

Reported hepatitis C virus (HCV) coinfection rates range from 4% among HIV-infected non-drug users to 89% among HIV-infected injection drug users (IDUs).1014 In a recent study of men who have sex with men, 26% of men who reported that they were HIV-infected were also HCV-infected.15 Hypocholesteremia has been associated with HCV infection in both the general population and among HIV-infected persons.1618 Among persons with liver disease, hypocholesteremia may in some cases indicate decreased hepatic function and poor prognosis, however, lower total cholesterol and low-density lipoprotein cholesterol (LDL-C) have been reported with HCV infection independent of hepatic fibrosis or synthetic function.1618 Hepatitis C infection has also been linked to lower CRP levels.19,20 Because CRP is produced mainly by hepatocytes, it has been postulated that lower CRP in HCV-infected patients may reflect hepatocellular injury.20

It is therefore possible that HCV coinfection may, to some extent, ameliorate the increased cardiovascular risk indices that have been reported in HIV-infected persons. Our study sought to investigate associations of HCV with lipid and CRP levels in a well-characterized cohort of older HIV-infected and at-risk men, with high prevalence of HCV-infection, in the Bronx, New York.


Study design and participants

We performed a cross-sectional analysis of lipid and CRP levels among men participating in the Cohort of HIV At-Risk Aging Men's Prospective Study (CHAMPS), an ongoing longitudinal study of atherosclerosis, bone loss, and drug use in older men with or at risk for HIV infection recruited from the community in the Bronx, New York. Study design and participant recruitment have been described in detail previously.21 In brief, men within 1 year of their fiftieth birthday or older were eligible if they had HIV infection or were at risk for acquiring HIV through injection drug use, unprotected sex with men, having had five or more sexual partners within the prior 5 years, having exchanged sex for drugs or money, or having had unprotected sex with an injection drug user or with a woman known to have HIV infection. Participants attend semiannual research visits for standardized interviews, phlebotomy, and measurement of weight, height, waist circumference, and blood pressure. Between March 2003 and July 2004, 217 men in CHAMPS had fasting lipid and CRP levels measured. The Instituutional Review Boards at Montefiore Medical Center and Albert Einstein College of Medicine approved this study. All participants gave written informed consent.

Study procedures

Standardized interviews collected data on sociodemographic characteristics, HIV/HCV transmission risk factors, medical history, HIV disease status, antiretroviral and other medication use, alcohol use, cigarette smoking, diet, physical activity, and drug-use behaviors. Detailed information was collected on type (cocaine, heroin, or speedball) and route (injection, smoking, or snorting) of drug use. HIV/HCV transmission risk factors among the men in our study were classified as injection drug use, high-risk sexual activity (sex with an injection drug user or an HIV-infected partner, sex with men, exchanging sex for drugs/money, or having multiple sexual partners, defined as 5 or more partners within the past 5 years), or blood/blood product transfusion risk. Risk categories were not mutually exclusive, because it was possible for an individual to have more than one risk factor.

Dietary intake was measured using the modified Rapid Eating and Activity Assessment for Participants interview.22 Body mass index (BMI) was calculated as weight/(height)2 (kg/m2).23 Hypertension was defined as systolic blood pressure 130 mm Hg or more and/or diastolic blood pressure 85 mm Hg or more (mean of two measurements taken while the participant was sitting). Men who reported a history of hypertension and current use of antihypertensive medications were classified as hypertensive regardless of measured blood pressure.

For HIV-infected men, CD4 lymphocyte count and HIV viral load were measured at each visit, and for seronegative men, HIV serology repeated. Participants underwent oral glucose tolerance testing with phlebotomy for glucose determination immediately prior to, and 120 minutes after, ingestion of a 75-g glucose beverage.24 Fasting insulin was measured by double antibody radioimmunoassay in the Hormone Assay Core of the Einstein Diabetes Research and Training Center (intra-assay coefficient of variance, 7.2%; interassay coefficient of variance, 9.4%; cross-reactivity with proinsulin, 36.8%), and plasma glucose measured by hexokinase method. Insulin resistance was calculated using the homeostasis model assessment (HOMA-IR).25 Impaired glucose tolerance and diabetes were defined using American Diabetes Association criteria.26

Determination of hepatitis C status

Hepatitis C virus testing was performed using enzyme immunoassay (ELISA 3.0, Ortho Diagnostic Systems, Rochester, NY). For HCV seropositive participants, HCV ribonucleic acid (RNA) was quantified using the VERSANT HCV RNA assay (Bayer Corporation, Tarrytown, NY), with a lower limit of detection of 615 IU/mL. Hepatitis C infection was defined by the presence of HCV RNA.

Antiretroviral therapy classification

Published guidelines in use at study initiation were used to define HAART.27 Protease inhibitor-based HAART was defined as three or more ARV medications including at least one PI, and non-PI HAART as three or more ARV medications including at least one non-nucleoside reverse transcriptase inhibitor (NNRTI) or abacavir. Men were classified as being either (1) HIV-uninfected; (2) HIV-infected and antiretroviral-naïve (ARV-naïve); (3) HIV-infected and naïve to protease inhibitors (PIs) but currently taking non-PI HAART; or (4) HIV-infected and currently taking PI-based HAART.

Outcome measurement

Blood was drawn after a 10- to 12-hour overnight fast. Serum was separated within 20 minutes of collection and stored at −70°C until the day of the assay. Total cholesterol, triglycerides, and high-density lipoprotein cholesterol (HDL-C) were assayed by routine laboratory techniques using Lipids Research Clinics methodology.28 The low density lipoprotein cholesterol (LDL-C) level was measured directly (Olympus Diagnostics, Olympus America Inc., Melville, NY) because for patients with triglycerides greater than 400 mg/L, the Friedewald formula may be inaccurate.29 C-reactive protein was measured by high-sensitivity enzyme-linked immunosorbent assay (ELISA; ALPCO, Windham, NH) with intra-assay and interassay coefficients of variance of 7.04% and 11.04%, respectively, and a lower limit of detection of 0.002 mg/L.

Data analysis

Univariate analyses were performed using χ2, Fisher's exact, Student's t, Wilcoxon, or Kruskal-Wallis tests, as appropriate. Linear regression models were used to assess associations of HCV infection with total cholesterol, LDL-C, HDL-C, triglycerides, and CRP. Variables examined included HIV status, age, BMI, waist circumference, HOMA-IR, dietary intake, drug use and cigarette smoking, number of years since first injection drug use; and among HIV-infected men, HIV-1 viral load, CD4 cell count, and antiretroviral therapy group; as well as those factors with p ≤ 0.2 on univariate analyses.

Age was classified as less than or the median or greater value of 54 years. BMI and waist circumference were each explored as continuous variables in separate models. Dietary intake was classified as high in fiber and low in fat if participants reported rarely eating less than three servings of whole-grain/high-fiber products daily and had a dietary fat score at or below the median of the study population. Cocaine and heroin use were explored both as a combined variable and individually. Number of years since first injection drug use was included in the models as a surrogate for duration of HCV infection, because other studies have shown that acquisition of HCV infection occurs rapidly upon initiation of injection drug use, with 78% of drug users being HCV antibody-positive within the first year of injecting.30

Multivariate analyses were performed for the entire study sample and then separately for HIV-infected men. In the models for HIV-infected men, HIV-1 viral load was categorized as detectable (≥75 copies per milliliter) or undetectable. CD4 cell count was categorized as less than 200 cells/mm3, 200−499 cells/mm3, and 500 cells/mm3 or more. With respect to antiretroviral use, participants were classified as being (1) antiretroviral-naïve (ARV-naïve), (2) naïve to PIs but on non-PI HAART, or (3) on PI-based HAART. Triglycerides, HDL-C, and CRP were log-transformed in order to meet normality criteria for linear regression. Interaction terms were tested and model fit examined. Statistical analyses were performed using SPSS® (base 10.0, SPSS Inc., Chicago, IL) and SAS® (version 8.1, SAS Institute, Cary, NC) software. Statistical significance was determined using two-tailed tests with p < 0.05 considered to be significant.


Participant characteristics

Of the 217 men enrolled who had lipid levels, 24 had a history of a myocardial infarction or stroke and were therefore excluded from this analysis. No men were taking lipid-lowering medications. Hepatitis C results were available for 182 of the 193 men who were not excluded. One hundred ten men (60.4%) had detectable HCV RNA, and were classified as HCV-infected. Of the remaining 72 men, 48 men were anti-HCV negative and 24 were anti-HCV positive but had no detectable HCV RNA. Seventeen men (9%) reported ever receiving treatment for HCV infection and the two men (0.6%) reported use of interferon within 6 months prior to the study interview.

Men excluded from the study because of reported prior stroke or myocardial infarction did not differ significantly from those included with respect to the prevalence of HCV infection (66.7% vs. 60.4%, (p = 0.56), levels of total cholesterol (p = 0.56), LDL-C (p = 0.72), or triglycerides (p = 0.28), or CRP levels (p = 0.51). There were also no significant differences in lipid or CRP levels when excluded and included men were analyzed separately within the HCV-infected and HCV-uninfected groups.

Participant characteristics are shown in Table 1.

Table 1
Demographic and Clinical Characteristics of Participants by HCV Status

The median age was 54 years among both HCV-infected and HCV-uninfected men. Most men (89.1% of HCV-infected men and 87.5% of uninfected men) were aged 50−60 years, while 9.1% of HCV-infected and 9.7% of uninfected men were aged 61−70 (p = 0.97). Three men (2 HCV-infected and 1 uninfected) were over age 70. Ninety-seven of 118 HCV-infected men (88%) had ever injected drugs compared to 29% of HCV-uninfected men (p < 0.001). Similarly, a greater proportion of HCV-infected than HCV-uninfected men were currently using illicit drugs. The median number of years since first injection drug use was 35 years among HCV-infected men and 34 years among uninfected men (p = 0.21). Most men (92.3%) were either past or current cigarette smokers. HCV-infected men were more likely than HCV-uninfected men to smoke currently (p = 0.002), although pack-years of smoking did not differ between the HCV groups. Waist circumference, BMI, and dietary fiber/fat intake did not differ by HCV status.

One hundred eight men (59.3%) were HIV-infected, 69 (63.9%) of whom were coinfected with HCV. There was no significant difference in HCV prevalence by HIV serostatus. The median CD4 lymphocyte count among HIV-infected men was 342 cells/mmn (interquartile range [IQR] 216−522) and 57.4% had detectable HIV-1 viral load (>75 copies per milliliter). Approximately half of the HIV-infected men (54.6%) were taking PI-HAART, 21.3% were on non-PI HAART, and 24.1% were ARV-naïve.

Univariate analysis of lipid levels

Table 2 shows univariate analysis of lipid results. In the overall study sample, HCV-infected men had significantly lower mean total cholesterol (p < 0.01) and LDL-C (p < 0.01) than HCV-uninfected men. Triglycerides (p = 0.07) and HDL-C (p = 0.81) did not differ by HCV status. Among HIV-infected men, HCV infection remained significantly associated with lower total cholesterol and LDL-C.

Table 2
Lipid and C-Reactive Protein Levels, Stratified by HCV Status in the Overall Study Sample and in HIV-Infected Men

HIV-infected men had lower mean total cholesterol (152.0 4.1 versus 165.6 4.8 mg/dL, p < 0.01) and HDL-C (42.6 ± 1.6 versus 48.7 ± 1.6 mg/dL, p < 0.01), but higher triglycerides (134.9 ± 9.2 versus 106.0 ± 8.6 mg/dL, p < 0.01) than HIV-uninfected men. Among the HIV-infected men, PI use was associated with the highest total cholesterol (159.6 ± 5.8 mg/dL versus 132.8 ± 7.1 [ARV-naïve] and 154.3 ± 8.4 [non-PI HAART], p = 0.01) and triglycerides (150.1 ± 12.7 mg/dL versus 121.2 ± 22.8 and 111.3 ± 10.6, respectively, p = 0.045).

Multivariate analysis of lipids levels

Results of separate multivariate analyses in the overall study sample (Table 3) and among HIV-infected men (Table 4) showed that being HCV-infected was associated with lower total cholesterol, LDL-C, and triglycerides. HCV status was not associated with HDL-C (p = 0.92 in the overall sample, p = 0.99 among HIV-infected men, data not shown).

Table 3
Factors Associated with Lipids and CRP in the Overall Study Sample
Table 4
Factors Associated with Lipids and CRP Among HIV-Infected Men

After adjusting for HIV status, HOMA-IR, dietary intake of fat and fiber, and age, HCV-infected men had total cholesterol 32.51 mg/dL lower (95% confidence interval [CI] −44.52, −20.50; p < 0.001), and LDL-C 22.23 mg/dL lower (95% CI −31.20, −13.21; p < 0.001) than HCV-uninfected men. The effect on triglycerides was of smaller magnitude, with HCV-infected men having triglyceride levels 1.23 mg/dL lower than HCV-uninfected men, after adjusting for the covariates listed above (p = 0.01; data back-transformed). HIV-infected men had higher triglycerides (p = 0.001) than HIV-uninfected men. HOMA-IR was positively associated with triglycerides (p = 0.01) and LDL-C (p = 0.03).

Among HIV-infected men (Table 4), after adjusting for antiretroviral group, HIV-1 viral load, HOMA-IR, dietary fiber and fat intake, and age, HCV-infected men had lower total cholesterol (p < 0.001) and LDL-C (p < 0.001). The effect of HCV infection on triglycerides was modified by the antiretroviral group. Being HCV-infected was associated with lower triglycerides among men on PI HAART and non-PI HAART, but not among ARV-naïve men. Among PI-users, those who were HCV-infected had triglycerides 1.41 mg/dL lower than HCV-uninfected men (p = 0.02), while among men on non-PI HAART, those who were HCV-infected had triglycerides 1.58 mg/dL lower than HCV-uninfected men (p = 0.02). Among HCV-uninfected men, use of PI-HAART was associated with triglycerides 2.18 mg/dL higher compared to being ART-naïve (p = 0.001).

Among HIV-infected men, a detectable HIV-1 viral load was associated with lower total cholesterol (p = 0.04). A similar association with LDL-C did not reach statistical significance (p = 0.06). CD4 cell count was not significantly associated with total cholesterol (p = 0.68), LDL-C (p = 0.95), or triglycerides (p = 0.55), and its inclusion in the multivariate models did not change associations of HCV infection with these outcomes. Low-fat, high-fiber dietary intake was significantly associated with lower total cholesterol (p = 0.049) but not with LDL-C or triglycerides. Insulin resistance (HOMA-IR) remained positively associated with triglycerides (p = 0.049). Current cigarette smoking, pack-years of cigarette smoking, Current cigarette smoking, pack-years of cigarette smoking, heroin use, cocaine use, and number of years since first injection drug use were not associated with lipid levels in the overall study sample or among HIV-infected men.

Because a single undetectable HCV RNA level cannot exclude active infection, we repeated multivariate models for each outcome variable, comparing men with detectable HCV RNA levels to those known to be HCV-uninfected (i.e., negative for HCV antibody), after excluding men who were anti-HCV positive but had no detectable RNA. The statistical significance and magnitude of the association of HCV status with lower total cholesterol and LDL-C were essentially unchanged in these models. The association with triglycerides, while unchanged in the analysis of HIV-infected men, did not reach significance in the overall study sample (p = 0.11).

Univariate analysis of CRP

CRP results were available for 158 of 182 (87%) men (Table 2). Median CRP was 1.43 mg/L (IQR 0.57, 3.58). Sixty-one men (38.6%) had CRP less than 1 mg/L, 54 (34.2%) had CRP between 1 and 3 mg/L, and 43 (27.2%) had CRP greater than 3 mg/L. Waist circumference (r = 0.27, p < 0.01) and BMI (r = 0.23, p < 0.01) were positively correlated with CRP. Overall, HCV-infected men had significantly lower median CRP than HCV-uninfected men (1.03 versus 1.86 mg/L, p = 0.04). There was no significant difference in CRP between HCV-infected men who had ever received hepatitis C treatment and those who had not (1.84 mg/dL versus 1.01 mg/dL, p = 0.69). Among HIV-infected men, however, the difference based on HCV status was not statistically significant (1.30 mg/L among HCV-infected men versus 1.78 mg/L among HCV-uninfected, p = 0.62). HIV serostatus was not significantly associated with CRP (p = 0.33). Among HIV-infected men antiretroviral group, CD4 lymphocyte count, and HIV-1 viral load were not associated with CRP.

Multivariate analysis of CRP

HCV-infected men had significantly lower CRP in multivariate analysis of both the overall study sample (Table 3) and among HIV-infected men (Table 4). After adjusting for HIV status, waist circumference, pack–years of cigarette smoking, and age, HCV-infected men had CRP 2.47 mg/L lower than HCV-uninfected men (p < 0.001). Waist circumference (p = 0.001) and pack–years of smoking (p = 0.003) were positively associated with CRP. HIV status was not associated with CRP.

Exclusion of those men who reported ever receiving HCV treatment from the sample did not change the significance or magnitude of associations for the covariates in the model.

Among HIV-infected men, after additionally adjusting for antiretroviral group and viral load, HCV-infected men had CRP 2.44 mg/L lower than HCV-uninfected men (p = 0.004). There was no significant association of CD4 cell count with CRP (p = 0.60) and its inclusion in the multivariate model did not change the association of HCV infection with lower CRP levels. Heroin use, cocaine use, and number of years since first injection drug use were not associated with CRP in either model. A separate model of CRP comparing HCV-infected men to anti-HCV negative men did not change the magnitude or significance of these associations.


This study of a well-characterized cohort of HIV-infected and at-risk men, in or older than the fifth decade of age, found a strong association between HCV-infection, defined by the detection of HCV RNA, and lower total cholesterol, LDL-C, triglyceride, and CRP levels. This association was highly significant in both the overall study sample as well as in men who were HIV-infected. Among HIV-infected men, HCV modified the effect of PIs on triglycerides so that HCV coinfected PI users had lower triglycerides than HCV-uninfected PI users. Our findings confirm previous reports associating HCV infection with lower lipid levels and provide new evidence of its association with lower CRP levels in the HIV-infected population.16,31,32

Among HIV-infected men, HCV coinfection was associated with differences in total cholesterol (33.7 mg/dL lower than HCV-uninfected men) and LDL-C (23.2 mg/dL lower) that would be considered clinically meaningful. Similar differences in total cholesterol and LDL-C based on HCV antibody status have been reported by Polgreen et al.16 While they reported no HCV effect on triglycerides, we found a small but statistically significant decrease in triglycerides associated with HCV infection among men on HAART, but not among ART-naïve men. Likewise, Collazos et al.33 reported markedly lower rates of hyperlipidemia, (total cholesterol or triglycerides greater than 200 mg/dL) in association with HCV among HAART users but not among non-HAART users. In that longitudinal study, and in a similar cohort study by Patroni et al.,32 HCV coinfection predicted smaller HAART-associated increases in lipids compared to being HCV-uninfected.33

The biologic mechanism underlying the lower lipid levels seen in association with HCV infection has not been determined. Because the liver plays a pivotal role in cholesterol synthesis, impairment of hepatic synthetic function induced by chronic active hepatitis may lead to decreased secretion of very low-density lipoprotein (VLDL) and thus to lower total cholesterol and LDL-C levels. Although some studies have shown associations between reductions in lipid levels and histopathologic liver damage or hepatic inflammation,34,35 others have reported no significant associations.17,36

Lower lipid levels have been reported in patients with chronic hepatitis caused by HCV infection compared to those with Hepatitis B infection, suggesting an HCV-specific effect on lipids, either as a result of differential effects on liver function or a direct interaction with lipid metabolism.36 Some studies suggest that HCV core protein decreases activity of microsomal triglyceride transfer protein, leading to decreased hepatic VLDL assembly and secretion.37,38 In addition, there is evidence that HCV particles associate with LDL and VLDL particles in plasma and utilize the LDL receptor for cell binding, possibly leading to increased lipid uptake by cells.39,40 Lower serum lipid levels have been reported in HCV-infected patients with hepatic steatosis compared to those without steatosis, in particular in association with HCV genotype 3 infection.41,42 The impact of HIV-HCV coinfection on prevalence of hepatic steatosis remains unclear.4345 We were unable to assess the impact of HCV genotype on lipid levels because these data were not available in our study. However, a previous analysis of HCV-infected drug users in our community found that the majority (79%) of participants were infected with either genotype 1a or 1b, with only 5% prevalence of genotype 3a.10 Accordingly, we anticipate that the vast majority of our participants would similarly be genotype 1.

Notably, we also found markedly lower CRP in association with HCV infection. While this finding, which appears paradoxical in the presence of chronic inflammation, has not previously been reported among HIV-infected patients, it has been noted in other populations.19,20 Nascimento et al.20 reported lower CRP among HCV-seropositive hemodialysis patients, compared to HCV-seronegative controls also on hemodialysis. Similarly, HCV-infected patients initiating interferon alfa-2b treatment had lower baseline CRP than uninfected controls.19 Secretion of CRP occurs primarily in the liver and it is therefore plausible that impaired hepatic function associated with chronic hepatitis may lead to decreased expression of CRP in HCV-infected patients. Interestingly, Kalabay et al.19 found no change in CRP among those HCV-infected patients who showed a virologic response to interferon alfa-2b treatment (at least 90% decrease in HCV RNA after 3 months of therapy), suggesting that factors other than viral replication may contribute to the HCV-associated reduction in CRP.

Previous studies of HCV status in relationship to lipids and CRP have used primarily antibody testing for HCV classification.16,31,46 The fact that detectable HCV RNA more precisely identifies individuals with active HCV replication is a major strength of this study.

The absence of HCV RNA results for anti-HCV negative men is a limitation of our study, because immunosuppressed individuals infrequently may have detectable HCV RNA despite seronegativity.11,47 Sherman et al.,11 using an HCV EIA 2.0 assay, reported the presence of hepatitis C viremia in 5.5% of anti-HCV–negative patients. However, we previously found no persons with detectable HCV RNA among 139 anti-HCV–negative drug users, using a third-generation EIA 3.0 assay (the assay used for the current study).10 The availability of data on transaminase levels and markers of hepatic synthetic function would have strengthened this analysis. While we do not have such data, our study participants were ambulatory volunteers recruited from the community who were able to comply with scheduled research visits and therefore were unlikely to have debilitating end-stage liver disease. We were unable to assess the impact of recent interferon use on CRP levels in this study since the small number of men who reported recently receiving interferon (two men) precluded its use as a covariate in our multivariate analysis. Because we excluded individuals who had prior myocardial infarction or stroke from this analysis, we cannot generalize our study findings to populations with prior clinical cardiovascular events.

In summary, this study showed an association of HCV infection with markedly lower total cholesterol, LDL-C and CRP levels among older HIV-infected and at-risk men, and with lower triglycerides among HIV-infected men on HAART. Given the importance of lipids and CRP as atherosclerosis risk factors, and the need to accurately assess cardiovascular risk among HIV-infected persons, these findings have important implications for both clinicians and researchers. Our results suggest that HCV coinfection could play a protective role against development of dyslipidemia among HIV-infected persons. Although the known morbidity and mortality of liver disease from HCV coinfection remains the predominant focus of HCV evaluation among HIV-infected persons, evidence that HIV-HCV coinfected patients may be at lower risk of developing lipid abnormalities on HAART should be considered when assessing risks and benefits of different antiretroviral regimens. Lower CRP levels seen with HCV infection may also impact atherosclerosis risk, however, the predictive value of CRP as a surrogate cardiovascular risk marker has not yet been evaluated in this population. The findings of this study also highlight the need to include assessment of HCV status in studies of dyslipidemia and cardiovascular risk in the HIV-infected population. Further investigation is needed to elucidate the mechanisms underlying the lower lipid and CRP levels seen with HCV infection, and to determine relationships to liver inflammation and synthetic function.


The authors thank Nancy Budner, Renee Shanker, Metta Cantlo, Madeline Crespo-Figueroa, and Randy Teeter for study coordination; Cal Emery for data management, Galina Moskaleva for programming; the AIDS Research Program study interviewers; and all of the men who participated in CHAMPS.

Supported by the National Institute on Drug Abuse ([NIDA] R01 DA14998 and K23 DA015003); National Center for Research Resources (K12–RR1767203); and a General Clinical Research Center grant (M01–RR12248), a Center For AIDS Research grant (CFAR-5 P30 AI51519), and a Diabetes Research and Training Center grant (P60DK020541–28), awarded to the Albert Einstein College of Medicine of Yeshiva University/Montefiore Medical Center from the National Institutes of Health.


1. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003. [PubMed]
2. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients—Association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179–1193. [PubMed]
3. d'Arminio A, Sabin CA, Phillips AN, et al. Cardioand cerebrovascular events in HIV-infected persons. AIDS. 2004;18:1811–1817. [PubMed]
4. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation. 2004;109:1603–1608. [PubMed]
5. de Saint ML, Vandhuick O, Guillo P, et al. Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study). Atherosclerosis. 2006;185:361–367. [PubMed]
6. Dolan S, Hadigan CM, Killilea KM, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr. 2005;39:44–54. [PubMed]
7. Currier JS, Kendall MA, Zackin R, et al. Carotid artery intima-media thickness and HIV infection: Traditional risk factors overshadow impact of protease inhibitor exposure. AIDS. 2005;19:927–933. [PMC free article] [PubMed]
8. Bozette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348:702–710. [PubMed]
9. Mercie P, Thiebaut R, Lavignolle V, et al. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Annals of Medicine. 2002;34:55–63. [PubMed]
10. Strasfeld L, Lo Y, Netski D, Thomas DL, Klein RS. The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. J Acquir Immune Defic Syndr. 2003;33:356–364. [PubMed]
11. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34:831–837. [PubMed]
12. Tedaldi EM, Hullsiek KH, Malvestutto CD, et al. Prevalence and characteristics of hepatitis C virus coinfection in a human immunodeficiency virus clinical trials group: The Terry Beirn Community Programs for Clinical Research on AIDS. Clin Infect Dis. 2003;36:1313–1317. [PubMed]
13. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE. Hepatitis C and progression of HIV disease. JAMA. 2002;288:199–206. [PubMed]
14. Brau N, Bini EJ, Shahidi A, et al. Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area. Am J Gastroenterol. 2002;97:2071–2078. [PubMed]
15. Cohen DE, Russell CJ, Golub SA, Mayer KH. Prevalence of hepatitis C virus infection among men who have sex with men at a Boston community health center and its association with markers of high-risk behavior. AIDS Patient Care STDs. 2006;20:557–564. [PubMed]
16. Polgreen PM, Fultz SL, Justice AC, et al. Association of hypocholesteremia with hepatitis C virus infection in HIV-infected people. HIV Medicine. 2004;5:144–150. [PubMed]
17. Maggi G, Bottelli R, Gola D, et al. Serum cholesterol and chronic hepatitis C. Ital J Gastroenterol. 1996;28:436–440. [PubMed]
18. D'Arienzo A, Manguso F, Scaglione G, Vicinanza G, Bennato R, Mazzacca G. Prognostic value of progressive decrease in serum cholesterol in predicting survival in Child-Pugh C viral cirrhosis. Scand J Gastroenterol. 1998;33:1213–1218. [PubMed]
19. Kalabay L, Nemesanszky E, Csepregi A, et al. Paradoxical alteration of acute-phase protein levels in patients with chronic hepatitis C treated with IFN-alpha2b. Int Immunol. 2004;16:51–54. [PubMed]
20. Nascimento MM, Bruchfeld A, Suliman ME, et al. Effect of hepatitis C serology on C-reactive protein in a cohort of Brazilian hemodialysis patients. Braz J Med Biol Res. 2005;38:783–788. [PubMed]
21. Klein RS, Lo Y, Santoro N, Dobs AS. Androgen levels in older men who have or who are at risk of acquiring HIV infection. Clin Infect Dis. 2005;41:1794–803. [PMC free article] [PubMed]
22. Segal-Isaacson CJ, Wylie-Rosett J, Gans KM. Validation of a short dietary assessment questionnaire: The Rapid Eating and Activity Assessment for Participants short version (REAP-S). Diabetes Educ. 2004;30:774, 776, 778. [PubMed]
23. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: Executive summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults. Am J Clin Nutr. 1998;68:899–917. [PubMed]
24. Diabetes mellitus Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1985;727:1–123. [PubMed]
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419. [PubMed]
26. American Diabetes Association Screening for type 2 diabetes. Diabetes Care. 2004;27:S11–S14. [PubMed]
27. Yeni PG, Hammer SM, Carpenter CC, et al. Anti-retroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002;288:222–235. [PubMed]
28. Myers GL, Cooper GR, Winn CL, Smith SJ. The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements. Clin Lab Med. 1989;9:105–135. [PubMed]
29. McNamara JR, Cohn JS, Wilson PW, Schaefer EJ. Calculated values for low-density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. Clin Chem. 1990;36:36–42. [PubMed]
30. Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 1995;74:212–220. [PubMed]
31. Di Giambenedetto S, Baldini F, Cingolani A, Tamburrini E, Cauda R, De Luca A. The influence of Hepatitis C virus coinfection on the risk of lipid abnormalities in a cohort of HIV-1–infected patients after inititation of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2004;36:641–642. [PubMed]
32. Patroni A, Torti C, Tomasoni L, et al. Effect of highly active antiretroviral therapy (HAART) and hepatitis C co-infection on hyperlipidemia in HIV-infected patients: A retrospective longitudinal study. HIV Clin Trials. 2002;6:451–461. [PubMed]
33. Collazos J, Mayo J, Ibarra S, Cazallas J. Hyperlipidemia in HIV-infected patients: the protective effect of hepatitis C virus co-infection. AIDS. 2003;17:927–929. [PubMed]
34. Petit JM, Benichou M, Duvillard L, et al. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis. Am J Gastroenterol. 2003;98:1150–1154. [PubMed]
35. Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med. 1997;157:792–796. [PubMed]
36. Fabris C, Federico E, Soardo G, Falleti E, Pirisi M. Blood lipids of patients with chronic hepatitis: Differences related to viral etiology. Clin Chim Acta. 1997;261:159–165. [PubMed]
37. Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 2002;16:185–194. [PubMed]
38. Andre P, Perlemuter G, Budkowska A, Brechot C, Lotteau V. Hepatitis C virus particles and lipoprotein metabolism. Semin Liver Dis. 2005;25:93–104. [PubMed]
39. Thomssen R, Bonk S, Propfe C, Heermann KH, Kochel HG, Uy A. Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol (Berl) 1992;181:293–230. [PubMed]
40. Wunschmann S, Medh JD, Klinzmann D, Schmidt WN, Stapleton JT. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J Virol. 2000;74:10055–10062. [PMC free article] [PubMed]
41. Hofer H, Bankl HC, Wrba F, et al. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol. 2002;97:2880–2885. [PubMed]
42. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33:1358–1354. [PubMed]
43. Ristig M, Drechsler H, Powderly WG. Hepatic steatosis and HIV infection. AIDS Patient Care STDS. 2005;19:356–65. [PubMed]
44. Marks KM, Petrovic LM, Talal AH, Murray MP, Gulick RM, Glesby MJ. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis. 2005;192:1943–1949. [PubMed]
45. Matos CA, Perez RM, Pacheco MS, et al. Steatosis in chronic hepatitis C: Relationship to the virus and host risk factors. J Gastroenterol Hepatol. 2006;21:1236–1239. [PubMed]
46. Visnegarwala F, Chen L, Raghavan S, Tedaldi E. Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection. J Infect. 2005;50:331–337. [PubMed]
47. Bonacini M, Lin HJ, Hollinger FB. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr. 2001;26:340–344. [PubMed]
PubReader format: click here to try


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...